GLP-1 receptor agonists like semaglutide and retatrutide are increasingly used off-label to curb alcohol cravings. But the metabolic and neurochemical shifts they trigger can leave executive function feeling threadbare. Cerebrolysin and Selank, two peptides with very different mechanisms, are being stacked to protect cognition while the GLP-1 does its work on craving. This article maps what that stack looks like, where it helps, and where the evidence runs thin.

Why GLP-1s Blunt Executive Function Even as They Cut Cravings

Semaglutide reduces alcohol intake in rodent models and early human reports. It slows gastric emptying, shifts reward signaling, and alters glucose handling in the brain. Those changes can lower motivation for alcohol but also for complex planning, working memory, and task switching. Users describe a kind of cognitive flatness: fewer intrusive thoughts about drinking, yes, but also less mental spark for work or creative projects. Retatrutide, a triple agonist, may amplify this through stronger metabolic disruption. The brain needs time to adapt to new energy substrates and altered dopamine tone. That adaptation window is where neurotrophic support becomes relevant.

Executive function depends on prefrontal cortex circuits that are sensitive to energy supply and neurotrophic factors. GLP-1s can transiently reduce glucose availability in certain brain regions. They also modulate BDNF expression in ways that are not fully mapped. The result is often a measurable dip in cognitive flexibility and sustained attention, especially in the first 6 to 12 weeks of treatment. Some users report this as "brain fog." Others notice they simply cannot hold a complex plan in mind the way they used to. This is not universal, but it is common enough to drive interest in countermeasures.

Cerebrolysin: The Neurotrophic Heavyweight

Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain tissue. It has decades of use in stroke, traumatic brain injury, and vascular dementia across Europe and Asia. Its proposed mechanism is broad: it mimics endogenous neurotrophic factors, promotes neuronal survival, and enhances synaptic plasticity. For executive function, the relevant effects are on prefrontal and hippocampal circuits. Cerebrolysin increases BDNF and NGF signaling, which supports the very networks that GLP-1s can temporarily destabilize. A typical protocol is 5 to 10 mL intramuscularly, five days per week, for four to eight weeks. Cost runs around $48 per 10 mL vial from gray-market suppliers, making a month of treatment roughly $200 to $400 depending on dose and source.

But Cerebrolysin is not a stimulant. It does not produce an immediate cognitive lift. Its effects accumulate over weeks, and the evidence for healthy adults is much weaker than for clinical populations. Most studies involve patients with existing neurodegeneration or acute injury. Extrapolating to a biohacker using semaglutide for alcohol craving requires a leap. The peptide is also poorly characterized in terms of long-term safety when used repeatedly in otherwise healthy brains. Allergic reactions, though rare, can be severe. And the sourcing is a genuine concern: porcine-derived products carry theoretical prion risk, though no cases have been reported with Cerebrolysin specifically.

Selank: The Anxiolytic Modulator

Selank is a synthetic heptapeptide derived from tuftsin, an immunomodulatory fragment of IgG. It binds to GABA receptors in a way that reduces anxiety without heavy sedation. It also modulates BDNF expression and may stabilize enkephalin degradation, which affects mood and stress response. In the context of alcohol craving reduction, Selank addresses a different axis than Cerebrolysin. GLP-1s can increase anxiety during the early weeks as the brain adjusts to lower alcohol intake. Selank smooths that transition. It also appears to support attention under stress, which is exactly when executive function fails. A typical dose is 250 to 500 mcg intranasally or subcutaneously, once or twice daily. Cost is modest: around $30 to $50 per 10 mg vial, lasting two to four weeks.

Selank's evidence base is thinner than Cerebrolysin's. Most human studies are small, Russian, and focused on anxiety disorders or cognitive impairment in clinical populations. There are no controlled trials of Selank in alcohol use disorder, let alone in combination with GLP-1s. Its safety profile appears benign, but long-term data are absent. The peptide is also fragile: intranasal absorption is variable, and subcutaneous injection may be more reliable but less convenient. Some users report a mild stimulant effect at higher doses, which can interfere with sleep if taken late in the day.

Stacking Cerebrolysin and Selank: Timing, Dosing, and Rationale

The logic of combining them is complementary. Cerebrolysin provides structural support for prefrontal circuits over weeks. Selank provides acute modulation of anxiety and stress reactivity, which protects executive function in the moment. A common stack looks like this: Cerebrolysin 5 mL intramuscularly in the morning, five days per week, for eight weeks. Selank 250 mcg intranasally or subcutaneously, once in the morning and once in the afternoon, on days when cognitive demand is high or anxiety is elevated. Some users add Semax, a related peptide, for a more stimulant-like nootropic effect. But that triple stack increases complexity and cost without clear added benefit for most people.

Timing matters. Cerebrolysin is best taken early in the day because it can cause mild agitation in some users. Selank can be taken as needed, but consistent dosing appears to work better for baseline anxiety. The GLP-1 itself is typically dosed once weekly, so the peptides fill the daily gap. There is no known pharmacokinetic interaction between Cerebrolysin, Selank, and semaglutide or retatrutide. But all three affect glucose metabolism and neurotransmitter balance, so the combined effect is not simply additive. Monitoring blood glucose, sleep quality, and subjective cognitive load is sensible for the first month.

What the Evidence Actually Says

No published study has tested Cerebrolysin and Selank together in humans, with or without a GLP-1. The individual evidence for Cerebrolysin in cognitive impairment is moderate but from heterogeneous populations. The individual evidence for Selank in anxiety is promising but small. The evidence for GLP-1s in alcohol craving reduction is growing rapidly, with semaglutide leading and retatrutide close behind. But the interaction between GLP-1-induced metabolic shifts and peptide-based neurotrophic support is entirely uncharted. Posters in the BPC-157 thread on r/Peptides noted a similar pattern, though no formal study has tested it (PubMed).

This is general educational content. Personal health decisions should involve a qualified clinician familiar with your medical history.

One open question remains: does the neurotrophic support from Cerebrolysin actually accelerate the brain's adaptation to GLP-1s, or does it merely mask the temporary cognitive dip? If the former, the stack could shorten the adjustment window. If the latter, users may be trading a transient side effect for a longer-term dependency on peptides. The answer will require longitudinal data that does not yet exist. For now, the stack is a rational but unproven experiment, best approached with modest expectations and careful self-observation. For a related discussion on pairing Cerebrolysin with a GLP-1 for cognitive protection, see Cerebrolysin & Semaglutide Stack: Cognitive Shield During Rapid Weight Loss. And if you are considering adding Semax to the mix, the trade-offs around anxiolytic blunting are covered in Semax & Selank Stack: Countering Anxiolytic Blunting of Nootropic Gains During GLP-1 Trials for AUD.